• “Rigorous staging” is required to determine appropriate
patients to consider ISRT, including BM biopsy and FDG-
PET scan
• ISRT remains treatment of choice for stage I/II indolent
lymphomas and results in long term progression free
survival and possible “cure” for patients still in remission
past 10 years




